| DB00252 | Phenytoin | For the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. |
| DB00673 | Aprepitant | For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents). |
| DB01174 | Phenobarbital | For the treatment of all types of seizures except absence seizures. |
| DB01320 | Fosphenytoin | For the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery. It can also be substituted, short-term, for oral phenytoin. |
| DB00564 | Carbamazepine | For the treatment of epilepsy and pain associated with true trigeminal neuralgia. |
| DB00794 | Primidone | Primidone is commonly indicated for the management of grand mal, psychomotor, and focal epileptic seizures [L4645, FDA Label]. In addition, it has also been studied and utilized as an effective management of essential tremor [A39414, A39415, L4645]. |
| DB01201 | Rifapentine | For the treatment of pulmonary tuberculosis. |
| DB00418 | Secobarbital | For the Short-term treatment of intractable insomnia for patients habituated to barbiturates |
| DB00503 | Ritonavir | Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. |
| DB00250 | Dapsone | For the treatment and management of leprosy and dermatitis herpetiformis. |
| DB00448 | Lansoprazole | Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. [A4892][A177065][FDA Label] It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis.[FDA Label] Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. [FDA Label] Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. [FDA Label] Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy). [FDA Label] |
| DB01045 | Rifampicin | For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections. |
| DB00745 | Modafinil | To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy. |
| DB01115 | Nifedipine | For the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents). |
| DB09280 | Lumacaftor | When given in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene [FDA Label]. |
| DB06595 | Midostaurin | Investigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). |
| DB12070 | Letermovir | For use in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT) [FDA Label]. |
| DB11633 | Isavuconazole | - Indicated for patients 18 years of age and older for the treatment of invasive aspergillosis [FDA Label].
- Indicated for patients 18 years of age and older for the treatment of invasive mucormycosis [FDA Label], including patients where treatment amphotericin B is inappropriate [L1482]. |
| DB14568 | Ivosidenib | Ivosidenib is approved for use in the treatment of relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA-approved test [FDA Label]. |
| DB11753 | Rifamycin | Rifamycin is indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of _E. coli_. The status of the disease should not be complicated by fever or blood in the stool. To prevent drug-resistant bacteria, it is important to mention that the use of rifamycin for this indication should be only done in cases where the infection is proven or strongly suspected to be caused by bacteria.[L4802]
Travallers' diarrhea is very common problem affecting 20-60% of the travellers and it is defined as an increase in frequency of bowel movements to three or more loose stools per day during a trip abroad. This condition is rarely life threatening but in severe cases it can produce dehydration and sepsis. The most common cause of travellers' diarrhea is a pathogen and from the pathogens identified, bacteria is the most common cause followed by norovirus, rotavirus and similar viruses.[A39995] |
| DB06717 | Fosaprepitant | For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy. |
| DB01080 | Vigabatrin | For use as an adjunct in treatment resistant epilepsy, refractory complex partial seizures, and secondary generalized seizures. It is also used as monotherapy in infantile spasms in West syndrome. |
| DB01601 | Lopinavir | Indicated in combination with other antiretroviral agents for the treatment of HIV-infection. |
| DB00615 | Rifabutin | For the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. |
| DB01221 | Ketamine | Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.[L1336, FDA label]
Reports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses.[A31873] These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.[L1337, A31874] |
| DB06414 | Etravirine | Indicated as an adjunct therapy in the treatment of adult HIV-1 infections resistant to therapy with other NNRTIs and antiretroviral agents. |